Table 2 Tumor-to-organ ratios of in BALB/C nu/nu mice bearing SK-RC-52 OV xenografts.

From: Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts

 

[111In]In-DOTA-HE3-ZCAIX:2

[99mTc]Tc(CO)3-HE3-ZCAIX:2

[111In]In-DTPA-G250(Fab’)2

[111In]In-DTPA-G250(Fab’)2

4 h

4 h

4 h

24 h

Blood

63 ± 11a

23 ± 2d,e

2.1 ± 0.2b

67 ± 12

Lung

30 ± 3a

16 ± 2d,e

2.7 ± 0.4b

7 ± 1c

Liver

33 ± 2a

8 ± 2d,e

0.7 ± 0.3b

0.6 ± 0.2c

Spleen

37 ± 3a

24 ± 6d,e

0.7 ± 0.2b

0.6 ± 0.2c

Stomach

36 ± 4a

22 ± 6d,e

4.4 ± 0.6b

6 ± 3c

Duodenum

31 ± 8

19 ± 6d,e

2.4 ± 1.2b

3 ± 2c

Kidney

0.038 ± 0.008

0.04 ± 0.01d

0.029 ± 0.005

0.03 ± 0.01

Muscle

102 ± 20a

62 ± 6d,e

7.9 ± 0.7b

11 ± 1c

Bone

47 ± 8a

28 ± 3d,e

3.0 ± 0.5b

4 ± 1c

  1. Results are presented as %ID/g (the mean values and standard deviation for four mice).
  2. aSignificant difference (p < 0.05) between [111In]In-DOTA-ZCAIX:2 and [99mTc]Tc(CO)3-HE3-ZCAIX:2;
  3. bSignificant difference (p < 0.05) between [111In]In-DOTA-ZCAIX:2 and [111In]In-G250(Fab’)2 (4 h);
  4. cSignificant difference (p < 0.05) between [111In]In-DOTA-ZCAIX:2 and [111In]In-G250(Fab’)2 (24 h);
  5. dSignificant difference (p < 0.05) between [99mTc]Tc(CO)3-HE3-ZCAIX:2 and [111In]In-G250(Fab’)2 (4 h);
  6. eSignificant difference (p < 0.05) between [99mTc]Tc(CO)3-HE3-ZCAIX:2 and [111In]In-G250(Fab’)2 (4 h).
Back to article page